ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailMenu BurgerPositive ArrowIcon PrintIcon SearchSite TitleTitle ChevronIcon Twitter
Health Technology

Sumitomo Dainippon Pharma Co., Ltd.

  • 2,097.00 JPY
  • +37.00
  • +1.80%
  • Japan
    Jun 17, 2019
  • Ticker
    TKS(4506)
  • Prev. close
    2,060
  • Market cap (JPY)
    819,674.31M
  • Market cap (USD)
    7,542.43M
  • Shares
    397.90M

Business Summary

Sumitomo Dainippon Pharma Co., Ltd. engages in manufacturing, sale, import and export of pharmaceuticals products. It operates through the Pharmaceutical Business and Other Business segments. The Pharmaceutical Business segment handles the creation of new pharmaceutical products. The Other Business segment division includes food ingredients and additives, chemical products materials, veterinary drugs, and diagnostics. The company was founded on May 14, 1897 and is headquartered in Osaka, Japan.

Financial Highlights

Mar 2019 JPYUSD
Revenue459,267M4,141.47M
Gross Profit345,714M3,117.49M
Operating income62,911M567.30M
Income before tax65,046M586.55M
Net income48,627M438.49M
EBITDA76,887M693.33M
Diluted EPS122.391.10
Dividends Per Share280.25
Total Assets834,717M7,541.37M
Total liabilities336,579M3,040.87M
Total equity498,138M4,500.50M
Operating cash flow48,711M439.25M
Currency in JPYCurrency in USD

Historical Data

 Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019
Revenue 371,370M 403,206M 408,357M 466,838M 459,267M
Gross Profit 265,014M 293,016M 307,911M 347,955M 345,714M
Operating income 23,275M 36,929M 60,974M 79,643M 62,911M
Income before tax 33,755M 39,560M 42,781M 84,866M 65,046M
Net income 15,447M 24,697M 31,316M 53,448M 48,627M
EBITDA 42,501M 57,194M 73,687M 92,530M 76,887M
Diluted EPS 38.88 62.16 78.82 134.53 122.39
Dividends Per Share 18 18 20 28 28
Total Assets 711,583M 707,715M 779,072M 809,684M 834,717M
Total liabilities 260,562M 261,243M 366,804M 356,961M 336,579M
Total equity 451,021M 446,472M 412,268M 452,723M 498,138M
Operating cash flow 32,523M 52,486M 19,143M 93,420M 48,711M
 Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019
Revenue 3,380.50M 3,357.69M 3,771.04M 4,212.10M 4,141.47M
Gross Profit 2,412.36M 2,440.08M 2,843.45M 3,139.46M 3,117.49M
Operating income 211.86M 307.52M 563.07M 718.58M 567.30M
Income before tax 307.26M 329.43M 395.06M 765.71M 586.55M
Net income 140.61M 205.66M 289.19M 482.24M 438.49M
EBITDA 386.87M 476.28M 680.47M 834.86M 693.33M
Diluted EPS 0.35 0.51 0.72 1.21 1.10
Dividends Per Share 0.16 0.14 0.18 0.25 0.25
Total Assets 5,933.56M 6,296.67M 6,991.58M 7,613.38M 7,541.37M
Total liabilities 2,172.70M 2,324.32M 3,291.78M 3,356.47M 3,040.87M
Total equity 3,760.85M 3,972.34M 3,699.79M 4,256.91M 4,500.50M
Operating cash flow 296.04M 437.07M 176.77M 842.89M 439.25M

Valuation Measures

Mar 2019
PER22.36
ROA5.91%
ROE10.22%
Operating margin13.69%
Profit margin10.58%

Key executives

  • President & Representative Director: Hiroshi Nomura
  • Director, Executive Officer & GM-Development: Nobuyuki Hara
  • General Manager-Research Technology: Yoshiharu Ikeda
  • Director & Executive Officer: Toru Kimura
  • Executive Officer: Antony Loebel

Shareholders

  • Sumitomo Chemical Co., Ltd. (51.6%)
  • Inabata & Co., Ltd. (5.1%)
  • Nomura Asset Management Co., Ltd. (3.3%)
  • Nippon Life Insurance Co. (1.9%)
  • Nikko Asset Management Co., Ltd. (1.7%)
  • Sumitomo Mitsui Banking Pension Fund (1.7%)
  • Daiwa Asset Management Co. Ltd. (1.6%)
  • Sumitomo Life Insurance Co. (1.4%)
  • MS&AD Insurance Group Holdings, Inc. (1.4%)
  • The Vanguard Group, Inc. (1.0%)

Contact Details

Related Companies

  • Dainippon Sumitomo Pharma America Holdings, Inc.
  • Sunovion Pharmaceuticals Asia Pacific Pte Ltd.
  • Sumitomo Pharmaceuticals (Suzhou) Co. Ltd.
  • Sunovion Pharmaceuticals Europe Ltd.
  • Sumitomo Dainippon Pharma Trust
  • Sumitomo Dainippon Pharma Employee Stock Ownership Plan
  • Kyowa Hakko Pharmaceuticals (Suzhou) Co. Ltd.
  • Tanabe Seiyaku Co., Ltd. /Pet Medicine Operations/
  • Tolero Pharmaceuticals, Inc.
  • Boston Biomedical, Inc.
  • Sunovion Pharmaceuticals, Inc.

Competitors

  • Intra-Cellular Therapies, Inc.
  • DURECT Corporation
  • VistaGen Therapeutics, Inc.
  • Vanda Pharmaceuticals Inc.
  • ACADIA Pharmaceuticals Inc.
  • Adamas Pharmaceuticals, Inc.
  • Xenon Pharmaceuticals Inc.
  • Voyager Therapeutics, Inc.
  • Cyclacel Pharmaceuticals, Inc.
  • Innoviva, Inc.
  • Neos Therapeutics, Inc.
  • Axovant Gene Therapies Ltd.
  • Marinus Pharmaceuticals Inc
  • Stemline Therapeutics, Inc.
  • Verona Pharma plc
  • Circassia Pharmaceuticals Plc
  • Supernus Pharmaceuticals, Inc.
  • Acorda Therapeutics, Inc.
  • ArQule, Inc.
  • OptiNose, Inc.
  • Qurient Co., Ltd.
  • SCYNEXIS, Inc.
  • Aravive, Inc.
Last Updated on 17 Jun, 2019

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Get Unlimited access

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends June 30th

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media